Home Newsfeeds Morgan Stanley Maintains Overweight on Take-Two Interactive, Lowers Price Target to $145

Morgan Stanley Maintains Overweight on Take-Two Interactive, Lowers Price Target to $145

Morgan Stanley analyst Matthew Cost maintains Take-Two Interactive (NASDAQ:TTWO) with a Overweight and lowers the price target from $150 to $145.

byBenzinga Newsdesk

November 28, 2022

1 minute read

Morgan Stanley analyst Matthew Cost maintains Take-Two Interactive (NASDAQ:TTWO) with a Overweight and lowers the price target from $150 to $145.

HC Wainwright & Co. Maintains Buy on Freeline Therapeutics, Lowers Price Target to $15

By Benzinga Newsdesk

August 22, 6:05 AM

HC Wainwright & Co. analyst Patrick Trucchio maintains Freeline Therapeutics (NASDAQ:FRLN) with a Buy and lowers the price target from $20 to $15.

FRLN

Informatica Sees Q3 Revenue $395M-$405M Vs $403.28M Est.; FY23 Revenue $1.57B-$1.59B Vs $1.58B Est.

By Happy Mohamed

August 2, 4:14 PM

Third Quarter 2023 Ending September 30, 2023: GAAP Total Revenues are expected to be in the range of $395 million to $405 million, representing approximately 8% year-over-year growth at

INFA

Sarissa Capital Submits Notice To Call A Special Meeting Of Amarin Shareholders To Add Directors And Remove Chairman Per Wold Olsen

By Benzinga Newsdesk

January 10, 2:36 PM

Sarissa believes current board lacks any remaining credibility for representing shareholders Sarissa is astonished that Amarin board refuses to add shareholder representatives

AMRN

Emerson Q2 Outlook: Adj. EPS $1.22 – $1.26 Vs. $1.25 Estimate, GAAP EPS $0.68 – $0.72 Vs. $0.74 Estimate, Revenue Growth 12.5% – 14.5%

By Benzinga Newsdesk

February 7, 7:58 AM

2024 Outlook The following tables summarize the fiscal year 2024 guidance framework. The 2024 outlook assumes approximately $500 million returned to shareholders through share repurchases and approximately $1.2 billion

EMR

Morgan Stanley Maintains Overweight on Take-Two Interactive, Lowers Price Target to $145

Related Posts

HC Wainwright & Co. Maintains Buy on Freeline Therapeutics, Lowers Price Target to $15

Informatica Sees Q3 Revenue $395M-$405M Vs $403.28M Est.; FY23 Revenue $1.57B-$1.59B Vs $1.58B Est.

Sarissa Capital Submits Notice To Call A Special Meeting Of Amarin Shareholders To Add Directors And Remove Chairman Per Wold Olsen

Emerson Q2 Outlook: Adj. EPS $1.22 – $1.26 Vs. $1.25 Estimate, GAAP EPS $0.68 – $0.72 Vs. $0.74 Estimate, Revenue Growth 12.5% – 14.5%